Myo-inositol for the Management of Poor Ovarian Responders: A Prospective Randomized Controlled Trial
Launched by AMERICAN UNIVERSITY OF BEIRUT MEDICAL CENTER · Feb 14, 2020
Trial Information
Current as of June 25, 2025
Unknown status
Keywords
ClinConnect Summary
The management of poor ovarian responders (POR) remains the most challenging in In-Vitro Fertilization (IVF). The incidence of POR ranges between 9 and 24% (Caprio F, et al, 2015).
POR refers to a reduction in the quantity of primordial follicle pool in reproductive age group (Jirge, P. R., 2016, Sunkara, S. K., et al, 2014), in addition to a higher risk of implantation failure (Kailasam C, et al, 2004).
To overcome this condition, adjuvant fertility treatments using controlled ovarian stimulation along with IVF is needed to achieve pregnancy. Despite the use of various treatments includi...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Age: 18-44 years at the time of interview
- • POR patients defined as: AMH\<1.5 ng/nl, AFC of 7 or less, 5 oocytes or less retrieved in a previous cycle
- * Patients undergoing controlled ovarian stimulation for any indication:
- • Male factor
- • Female factor
- Exclusion Criteria:
- • Patients with diabetes, thyroid dysfunction
- • Patients with abnormal uterine cavity
About American University Of Beirut Medical Center
The American University of Beirut Medical Center (AUBMC) is a leading academic medical institution in the Middle East, dedicated to advancing healthcare through innovative research, education, and clinical excellence. As a prominent sponsor of clinical trials, AUBMC integrates cutting-edge scientific inquiry with patient-centered care to enhance therapeutic options and improve health outcomes. With a commitment to ethical standards and regulatory compliance, AUBMC collaborates with multidisciplinary teams to conduct rigorous trials that contribute to the global medical knowledge base and address critical health challenges in the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beirut, , Lebanon
Patients applied
Trial Officials
Antoine Abu Mussa, MD
Principal Investigator
American University of Beirut Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials